Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
AltaThera Pharmaceuticals LLC operates within the Biotechnology & Pharmaceuticals technology area with a portfolio currently facing 2 pending office actions. Notably, these actions are distributed across 1 distinct examiner, which indicates that the 1 examiner is reviewing the active matters for the company. This concentration is further reflected in the involvement of only 1 distinct art unit, suggesting a narrow technical focus for the pending applications.
BARSKY, JARED is the busiest examiner for this portfolio, managing 2 busiest examiner pending office actions. This means that the company's current office action responses are directed to the same examiner. For a patent practitioner, this situation allows for a consistent advocacy approach, as the arguments presented in an application are likely to be seen and evaluated by the same official in the other. However, it also means that the company's immediate success in the Biotechnology & Pharmaceuticals space is highly sensitive to the specific examination style of BARSKY, JARED.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 2 | 50.2% | +22.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18126561 | METHODS OF ADMINISTERING SOTALOL HYDROCHLORIDE | BARSKY, JARED | 125d overdue |
| 18417748 | METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING | BARSKY, JARED | 121d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18417748 | METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING | BARSKY, JARED | 1628 | §103 | Final Rejection | 121d overdue | Pending | Jan 19, 2024 |
| 18126561 | METHODS OF ADMINISTERING SOTALOL HYDROCHLORIDE | BARSKY, JARED | 1628 | §103 | Final Rejection | 125d overdue | Pending | Mar 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial